Our why

We are uncovering something big in immuno-oncology. It’s called normunity.

That’s the name of our company, and we are pioneering cancer-fighting medicines that target novel immuno-oncology mechanisms. It’s also our new approach that treats cancer by restoring normunity – or the state of normal immunity – by removing cancer’s barriers to normal immune system function.

 

normunity.

/‘nôrm’/yo͞onədē/
  1. An organization that reveals cancer’s biggest secrets and removes its defenses by interrogating it in a humanly relevant manner to treat all cancers
  2. The restored state of normal immunity

A team like no other

We are able to pursue first-ever drug discovery in immuno-oncology because of our unparalleled team and partnership. Normunity was founded based on an ongoing partnership with the lab of Dr. Lieping Chen, a luminary in the field of immuno-oncology, at the Yale School of Medicine.

The team from Normunity and the Chen lab is deeply integrated and collaborative, bringing together a fusion of expert oncology minds in scientific discovery and drug development. It’s a powerful and invigorating partnership focused on a singular goal: to open up vast new opportunities to treat more cancers by targeting and disrupting novel mechanisms that interfere with normal cancer-fighting immunity.

Together with the Chen lab, our work identifies novel mechanisms using proprietary platforms that methodically interrogate the interactions between cancer and the immune system using human cells and tissues. Our Normunity team is led by highly experienced leaders with track records for pushing boundaries in pursuit of novel immuno-oncology medicines. Our pioneering spirit and drive to help cancer patients is already actively set in motion with our pipeline of cancer therapies – called immune normalizers – designed to restore normunity.

 

Leadership.

 
Rachel Humphrey, MD
Founding Chief Executive Officer
Rachel Humphrey, MD
Founding Chief Executive Officer

Rachel Humphrey has over 25 years of experience in clinical drug development, particularly in the field of cancer treatments and immunotherapies. Highlights of her career include leading the development of multiple blockbuster cancer therapies:  the CTLA-4 inhibiting immunotherapy Yervoy® (ipilimumab) at BMS, the PD-L1 inhibiting immunotherapy Imfinzi® (durvalumab) at AstraZeneca, and the kinase inhibitor cancer drug Nexavar® (sorafenib) at Bayer. After working at these big pharmaceutical companies, Rachel took her drug development expertise to emerging biotech companies, where she served in the role of Chief Medical Officer at Black Diamond Therapeutics, CytomX Therapeutics and Mirati Therapeutics, respectively. She previously served on the Board of Directors of CytomX Therapeutics and Xilio Therapeutics, respectively, and currently serves on the Board of Directors of Pyxis Therapeutics and Sporos Bioventures. Rachel started her career as an oncology fellow and staff physician at the National Cancer Institute. She received her training in internal medicine at The Johns Hopkins Hospital, her MD from Case Western Reserve Medical School, and her B.A. from Harvard University.

Lieping Chen, MD, PhD
Scientific Founder; United Technologies Corp. Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology), Yale School of Medicine
Lieping Chen, MD, PhD
Scientific Founder; United Technologies Corp. Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medicine (Medical Oncology), Yale School of Medicine

Dr. Lieping Chen is an immunologist known for his works in T cell biology, cancer immunology, and translational research to develop new treatments for human diseases, especially in the development of anti-PD-1/PD-L1 cancer immunotherapy. Prior to joining Yale Medical School, he was a faculty member at Johns Hopkins University School of Medicine, a faculty member at Mayo Clinic, and a scientist for the pharmaceutical company, Bristol-Myers Squibb.

Dr. Chen’s discoveries directly led to the development of anti-PD-1/PD-L1 cancer immunotherapy against broad spectrum of human cancers, and his work in the discovery of the PD-1/PD-L1 pathway
was cited as the #1 breakthrough of the year by Science magazine in 2013. He did the first proof-of-concept study in 1992 showing that the B7-CD28 family molecules could be the targets for cancer immunotherapy by introducing B7-1 into tumor cells to enhance therapeutic immunity. In 1999, he discovered PD-L1 (also called B7-H1) molecule and subsequently demonstrated the role of PD-L1 in the evasion of tumor immunity, and established the PD-1/PD-L1 pathway as the target for cancer immunotherapy. He also initiated and help organized the first-in-man clinical trial of anti-PD-1 antibody for treating human cancer and developed PD-L1 staining as a biomarker to predict treatment outcome. His laboratory also discovered many molecular pathways with immune modulatory functions and their applications in human disease treatment. These pathways include 4-1BB (CD137), ICOS/B7-H2, B7-H3, B7-H4, B7-H5/CD28H, PD-1H (VISTA), LIGHT/HVEM, RELT, TROY, B7-H2/CD28/CTLA-4 (human), SALM5/HVEM, FGL1/LAG-3, Siglec-15. These discoveries have led to the development of therapeutic agents in various stages of clinical trials for the treatment of human cancer.

Dr. Chen had his medical training in Fujian Medical University and his fellowship in immunology/ oncology in Peking Union Medical College in Beijing. He moved to U.S. to earn a PhD degree from Drexel University College of Medicine. He is a member of the National Academy of Sciences and a fellow of the American Association for Cancer Research. Dr. Chen has published over 370 peer-reviewed research articles.

Olga Granaturova, MBA
Chief Operating Officer and Chief Business Officer
Olga Granaturova, MBA
Chief Operating Officer and Chief Business Officer

Ms. Granaturova brings over 25 years in the global biopharma industry with diverse experience that spans the entire value chain from R&D to regulatory development and commercial launch in biotechnology and pharmaceutical companies across many sizes and stages of growth. She brings deep expertise in business functions including corporate strategy, business development, fundraising, licensing, partnering and M&A transactions. Previously, she held business leadership roles involving company creation and biotech start-ups as co-founder and Chief Operating Officer of Parthenon Therapeutics, as VP of business development at Evotec, and as founder and managing partner of the life sciences consulting firm, LENUS Group. Earlier in her career, Olga had tenures at top tier pharmaceutical companies, including as a leader in global regulatory development at Merck and as a drug discovery scientist at Pfizer. Over the course of her career, Olga has led teams to deliver 20 different clinical candidates, 3 drug launches, and several multi-year, multi-million dollar deals. In addition, Olga serves on the board of Parthenon Therapeutics and Coucou Nous Voilou, a pediatric oncology nonprofit organization, and she is co-founder of Brighter Ventures, a group advancing women-led entrepreneurship. She was named to Inc.’s Female Founders 100 List, honoring women innovators. Olga received a BS in Pharmaceutical Sciences from SUNY at Buffalo and a TRIUM Global MBA from the NYU Stern School of Business, HEC Paris and the London School of Economics.

William LaRochelle, PhD
Chief Scientific Officer
William LaRochelle, PhD
Chief Scientific Officer

Bill LaRochelle has over 30 years of experience in translational research and drug development in the biotechnology/pharmaceutical industry and federal government, with experience building multiple successful drug discovery and development programs, as well as implementing R&D strategies for novel drug products. He had a 16-year tenure at Roche, including as Clinical Sciences Director at Roche Diagnostics, focusing on integrating next-generation sequencing and digital PCR platforms in the development of precision medicines. Also at Roche, he served as Scientific Director and Head of Healthcare Business Development, and the Head of Key Opinion Leader Relationships. Prior to this, Bill spent 8 years at CuraGen Corporation, where he directed the Translational Oncology Program, and he was responsible for initiating, conducting and managing translational oncology research activities resulting in four INDs for novel cancer drugs. Prior to joining CuraGen, Bill was a principal investigator at the National Cancer Institute at the National Institutes of Health where his research focused on oncogene/growth factor signal transduction and monoclonal antibodies in cancer and inflammation. He is an author of over 80 peer-reviewed publications, numerous patents, and the editor of the Oncogenomics Handbook. He received an American Cancer Society postdoctoral fellowship to study at the National Cancer Institute, earned a Ph.D. in biochemistry at Dartmouth Medical School, and a B.S. in biochemistry from Manhattan College.

Scott Phillips
Chief Financial Officer
Scott Phillips
Chief Financial Officer

Scott Phillips has led finance organizations over the past 25 years from startup organizations through large multinational commercial organizations.  Scott spent much of his biotech career at Alexion Pharmaceuticals where he served over 10 years in senior financial leadership roles as the company expanded from a pre-commercial business to a global commercial organization with over $4 billion in revenue.  At Alexion, he led Global Business Finance, a finance organization comprised of strategic finance, financial planning and analysis, and finance business partnership and also served as Chief Accounting Officer, in both cases leading global teams.  Scott led finance diligence and integration teams for multiple acquisitions and was involved in over $5 billion of debt and equity financings, as well as complex projects encompassing all disciplines of finance.  More recently, Scott has served as CFO and Head of Finance for public stage clinical development companies and has also served as a leader for venture-backed biotech companies, supporting these from the earliest stages of their life cycle, including financing, through their operations as a public company.  Scott is a Certified Public Accountant who served as a Senior Manager in the technology practice of a Big 4 accounting firm, specializing in venture-backed companies, acquisitions and initial public offerings.   He has a B.S. Business Administration and Masters of Accounting from the University of North Carolina at Chapel Hill.

Saul Fink, PhD
Sr Vice President, CMC/Manufacturing and Nonclinical Development
Saul Fink, PhD
Sr Vice President, CMC/Manufacturing and Nonclinical Development

Saul Fink has over 30 years of experience in CMC/manufacturing, nonclinical development, business transitions, and operational performance in the biotech/pharmaceutical industry. He has led CMC and nonclinical teams across many therapeutic areas for both small molecule and biologic assets. Saul most recently worked with Goldfinch Bio where he led teams in support of CMC strategic guidance, budgets, and all operational activities to establish a supply chain for clinical supplies. He also led all strategic and operational aspects for nonclinical development (toxicology, pharmacology, etc.). Saul spent a good part of his career in the pharmaceutical industry with Bristol-Myers Squibb (BMS). In these roles, he worked closely with C-suite and other senior executives to accelerate strategy execution, business transformations and operational performance in R&D and Global Manufacturing & Supply organizations. Saul led a multi-disciplinary, global integration manufacturing team following the acquisition of Amylin Pharmaceuticals by BMS and AstraZeneca (AZ). He then participated in the $7B divestiture of the BMS diabetes portfolio to AZ. He started his career working for the Clorox Technical Center where he was responsibilities for several functions within the Analytical Research and Services Department. Saul received his B.S. in Chemistry from Millersville University and Ph.D. in Chemistry from the University of Houston. He is currently a member of the Millersville University Council of Trustees, serves on the scientific advisory board for Intrommune Therapeutics and he formerly served as a councilman for East Brunswick (NJ) township.

Melinda Merchant, MD, PhD
Senior Vice President of Clinical Development
Melinda Merchant, MD, PhD
Senior Vice President of Clinical Development

Melinda Merchant is a physician scientist with two decades of experience in clinical oncology research. Melinda brings a patient-first mentality to the Normunity team, with a drive to collaboratively translate scientific findings to address unmet needs in the clinic. As a board-certified Pediatric Hematologist & Oncologist, Melinda held faculty/staff positions at Memorial Sloan-Kettering Cancer Center and the National Cancer Institute, with a focus on sarcomas and immuno-oncology. She was a lead investigator on multiple pediatric immunotherapy clinical trials, including ipilimumab, nivolumab, and novel cell therapies. Since her move to industry in 2015, Melinda has been highly active in clinical development at the interface of laboratory to early phase clinical trials, directing clinical development of multiple first-in-human studies at AstraZeneca, and late-stage development experience as head of Translational Medicine and clinical lead of the phase 3 confirmatory study in sarcoma supporting approval of Tazverik® (tazmetostat). As a leader in pharma and biotech, Melinda has successfully grown teams of scientists and physician scientists to collaboratively meet the challenges of drug development. Melinda received her MD and Ph.D. at the University of Miami School of Medicine and Department of Immunology & Microbiology, trained in pediatrics at Children’s National Medical Center, and completed fellowship at the National Cancer Institute in a combined program with Johns Hopkins Hospital.

Stephane Marzabal, PhD
Head of Program Leadership (consultant)
Stephane Marzabal, PhD
Head of Program Leadership (consultant)

Stephane Marzabal brings more than 20 years of experience in drug discovery, translational research, clinical development, commercialization, and global program leadership in biotech and pharma companies, primarily focused on oncology. He also has extensive leadership experience in implementing operating models and change management to support high-performance in R&D organizations.
In his previous roles, Stephane worked at Baxalta to lead the co-development, product approvals, and global launch of ONIVYDE® in pancreatic cancer in partnership with Merrimack Pharmaceuticals. At Merck KGaA, Stephane was the lead for evofosfomide, a Phase 3 candidate developed in partnership with Threshold Pharmaceutical for soft tissue sarcoma, pancreatic cancer, and NSCLC. At Merck Serono, he was Global Program Team Leader for Rebif® in multiple sclerosis leading worldwide approvals and global launch, and later he led an oncology team across multiple phase 1 and phase 2 compounds advancing in clinical development. In 2017, Stephane co-founded SYNOV Solutions, a boutique consulting group that partners with biopharmaceutical companies to create high performing drug development teams and organizations. He earned a PhD in Molecular Biology from Paris VI and a BS in Biostatistics applied to Clinical Trials.

Kristin Robbins, RN, MBA
Executive Director, Program Management & Business Operations
Kristin Robbins, RN, MBA
Executive Director, Program Management & Business Operations

Kristin Robbins has over 20 years of experience in clinical drug and medical device development. Prior to Normunity, Kristin was the Head of Program Management and Program Manager for the lead program at Kaleido Biosciences in Urea Cycle Disorder which submitted an IND for KB195 and executed a subsequent Ph2 trial. Before Kaleido, she had a 10-year tenure at Hologic, Inc., a Women’s Health company, including as Director of Program & Portfolio Management in the Surgical and Breast Health Divisions, focusing on variety of technologies including the NovaSure Endometrial Ablation Device and the Brevera Breast Biopsy System among others. Earlier in her career, Kristin spent 3 years as a Program Manager at Boston Scientific in two different divisions, the Oncology division, working on implantable ports for the administration of fluids and drugs for oncology patients and the Endovations division, which was a unique “startup type” division within a large company concept to build a single use colonoscope. Kristin’s early work in medical devices was with Abbott Laboratories. Kristin started her career as a registered nurse at Highland Hospital in Rochester, NY. She received a B.S. in Nursing at the University of Rochester and her MBA from Northeastern University and has a Project Management Professional (PMP) Certification.

Elizabeth Yamashita, BS, RAC
Head of Regulatory Affairs (consultant)
Elizabeth Yamashita, BS, RAC
Head of Regulatory Affairs (consultant)

Liz Yamashita has over 35 years of experience in the Biopharmaceutical Industry with 25 years focused in the global regulatory affairs function. Liz has wide exposure to areas of the pharmaceutical business in small molecule and biotechnology CMC, clinical and nonclinical development, as well as marketing, and business development. Liz has held executive regulatory positions at Oncobiologics, Inc., and Savient Pharmaceuticals, Inc. In these roles, she managed all aspects of the regulatory function, strategy and operational work from initial FDA, EMA and other health authority interactions through marketing application approvals. She was a Principal Fellow at ImClone Systems (now Eli Lilly) providing regulatory expertise across the ImClone and Lilly biotech pipelines. As Vice President at ImClone Systems, she was responsible for Regulatory CMC strategy and Operations for development and commercial monoclonal antibody projects. Liz began her career at Bristol-Myers Squibb Company holding several positions of increasing leadership responsibility. While experienced in multiple therapeutic areas, her main regulatory focus and interest have been with Oncology and Immunology encompassing both small and large molecules. Liz received her B.S. degree in Chemistry from the University of Rochester and is US certified by the Regulatory Affairs Professionals Society.

Suzanne Wilson
Head of Clinical Operations (consultant)
Suzanne Wilson
Head of Clinical Operations (consultant)

Suzanne Wilson has over 30 years of experience in clinical research, most of which is in oncology. She has practical experience in clinical operations from day-to-day clinical project management for individual programs to ensure timelines and budgets are maintained, through to managing teams of project managers and overseeing US, European, Aisa and worldwide clinical programs. She has a proven track record in a number of roles, in managing multidisciplinary teams and working in challenging and high-pressure environments for successful submissions to the health authorities. Opportunities have included establishing clinical operations in small virtual companies (GenSpera), managing large global programs in a multi-national pharma company (Cephalon, now Teva, and Baxalta), working for a large and small CRO (PRA and Nexus). Her experience enables her to contribute to the strategy and successful implementation of clinical programs. Suzanne has a degree in Pharmacology (B.Sc.) from Portsmouth University, UK.

Board of Directors.

Tim Shannon, MD
Executive Chair; General Partner, Canaan
Tim Shannon, MD
Executive Chair; General Partner, Canaan

For more than 25 years, Dr. Timothy Shannon has been an entrepreneur, executive, researcher, professor, and practicing physician. He is Chairman of the Board of Normunity and a Venture Partner at Canaan Partners. He also serves or has served on the boards of several Canaan portfolio companies, including Arvinas (NASDAQ: ARVN), IDEAYA Biosciences (NASDAQ: IDYA), NextCure (NASDAQ: NXTC), CytomX (NASDAQ: CTMX), Spyryx Biosciences, Vivace Therapeutics, and VaxInnate Corporation.

Previously, Dr. Shannon was President and Chief Executive Officer of CuraGen, a biopharmaceutical company focused on oncology, after serving as Executive Vice President of R&D and Chief Medical Officer. He also held positions of increasing responsibility for Bayer’s Pharmaceutical Business Group, including Senior Vice President of Global Medical Development. Prior to his career in industry, he was an Assistant Professor in the Pulmonary and Critical Care Division at Yale University School of Medicine.

Dr. Shannon received his B.A. in Chemistry from Amherst College, his medical degree from the University of Connecticut, and completed his postgraduate medical training at the Beth Israel Hospital of Harvard Medical School and Boston University.

Sakae Asanuma, CFA, MBA
President & CEO, Taiho Ventures
Sakae Asanuma, CFA, MBA
President & CEO, Taiho Ventures

Mr. Sakae Asanuma established Taiho Ventures as the founding President in 2016. Prior to joining Taiho, he was President and CEO at Astellas Venture Management and US Head of Astellas Innovation Management in 2011-2015. Prior to Astellas, he worked for Yasuda Enterprise, a Japan/US-based VC firm in 2000-2011. He has invested in more than 50 biotech companies since 2000 and majority of his portfolios achieved IPOs or M&AS. During his tenure at Taiho and Astellas, he led to executed dozens of research collaboration deals with academia and biotech ventures, including several build-to-buys or spinouts.

Paulina Hill, PhD
Partner, Sanofi Ventures
Paulina Hill, PhD
Partner, Sanofi Ventures

Dr. Paulina Hill joined Sanofi Ventures in 2022 with a background in early-stage biotech investing and company building. Prior to joining Sanofi, Paulina was a Principal on the investment team at Omega Funds where she served as the board director or observer for Scorpion Therapeutics, Arrakis Therapeutics, IFM, and additionally led or co-led Omega’s investments in Theseus (NASDAQ: THRX), Ikena (NASDAQ: IKNA), Synthekine and Vanqua Bio.

Prior to joining Omega Funds, Dr. Hill began her career with Polaris Partners. She served on the boards of Kala Pharmaceuticals (NASDAQ: KALA), Neuronetics (NASDAQ: STIM) and Lyra Therapeutics (NASDAQ: LYRA), Microchips Biotech (acquired by Dare Biosciences), Arsenal Medical and CAMP4 Therapeutics, where she was the founding CEO.

Dr. Hill completed her postdoctoral fellowship in Professor Robert Langer’s lab in the Chemical Engineering department at the Massachusetts Institute of Technology (MIT). During her time at MIT, she founded the MIT Postdoctoral Association and served as its President. Paulina also served on the MIT Intellectual Property Committee. Paulina completed her PhD in Molecular Medicine from the Wake Forest University School of Medicine. Paulina graduated magna cum laude from East Carolina University with a quadruple major in biochemistry, neuroscience, biology, and chemistry. Paulina attended East Carolina University on a full athletic scholarship and served as the captain of the women’s varsity tennis team.

Lynn Yang, MS, MBA
Partner, Sequoia Capital China
Lynn Yang, MS, MBA
Partner, Sequoia Capital China

Mrs. Lynn Yang is a partner at Sequoia Capital China focusing on investment in innovative healthcare companies. Prior to joining Sequoia Capital China in May of 2015, she worked at healthcare investment team of Legend Capital. Lynn has led and participated in investments across all areas of venture growth and in different fields within the healthcare industry, including Cstone (2616.HK), Grail, Burning Rock, JW Therapeutics, Hongkong Asia Medical, Qihan Bio (eGenesis counterpart in China), Hifibio, and others.

Prior to her years in investment and venture capital, Lynn worked as business development manager at Johnson & Johnson and product manager at GE Healthcare. Mrs. Yang holds an MBA from Duke University and Master of Clinical Science from Huazhong Technology University.

Rachel Humphrey, MD
Founding Chief Executive Officer
Rachel Humphrey, MD
Founding Chief Executive Officer

Rachel Humphrey has over 25 years of experience in clinical drug development, particularly in the field of cancer treatments and immunotherapies. Highlights of her career include leading the development of multiple blockbuster cancer therapies: the CTLA-4 inhibiting immunotherapy Yervoy® (ipilimumab) at BMS, the PD-L1 inhibiting immunotherapy Imfinzi® (durvalumab) at AstraZeneca, and the kinase inhibitor cancer drug Nexavar® (sorafenib) at Bayer. After working at these big pharmaceutical companies, Rachel took her drug development expertise to emerging biotech companies, where she served in the role of Chief Medical Officer at Black Diamond Therapeutics, CytomX Therapeutics and Mirati Therapeutics, respectively. She previously served on the Board of Directors of CytomX Therapeutics and Xilio Therapeutics, respectively, and currently serves on the Board of Directors of Pyxis Therapeutics and Sporos Bioventures. Rachel started her career as an oncology fellow and staff physician at the National Cancer Institute. She received her training in internal medicine at The Johns Hopkins Hospital, her MD from Case Western Reserve Medical School, and her B.A. from Harvard University.

Scientific Advisory Board.

Roy Herbst, MD, PhD
Yale School of Medicine
Roy Herbst, MD, PhD
Yale School of Medicine

Dr. Herbst is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, Director of the Yale SPORE in Lung Cancer, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine. He has worked over several decades as a pioneer of personalized medicine and immunotherapy to identify biomarkers and bring novel targeted treatments and immunotherapies to patients, serving as principal investigator for numerous clinical trials testing these agents in advanced stage lung cancers. His research and clinical collaborations have led to the approval of several therapies (such as gefitinib, cetuximab, bevacizumab, axitinib, atezolizumab, and pembrolizumab), which have revolutionized the field and greatly enhanced patient survival. His work on “umbrella” trials has galvanized the field of targeted therapy and cancer drug approvals at the FDA. Nationally, he is at the forefront of personalized medicine and works closely with public-private partnerships to develop large clinical studies, such as Lung-MAP. The NCI Lung SPORE he leads has identified new mechanisms of sensitivity and resistance to immunotherapy.

Nils Lonberg, PhD
Canaan; previous SVP Oncology Discovery Biology at BMS
Nils Lonberg, PhD
Canaan; previous SVP Oncology Discovery Biology at BMS

Dr. Nils Lonberg has 30 years of operational experience in Biotech and Pharma, focusing on platform innovation, drug discovery, and drug development. Most recently, he was Senior Vice President, Oncology Discovery Biology, at Bristol-Myers Squibb, where he led drug discovery efforts for both targeted and immuno-oncology agents, including the checkpoint blockade therapies ipilimumab and nivolumab. Nils also has experience in startup and midsize biotech, serving as Scientific Director at GenPharm and Medarex. He received his PhD in Biochemistry and Molecular Biology from Harvard University and was elected to the National Academy of Engineering in 2015.

Mario Sznol, MD
Yale School of Medicine
Mario Sznol, MD
Yale School of Medicine

Dr. Mario Sznol is a Professor of Medicine (Medical Oncology) at Yale and Co-Director of the Cancer Immunology Program and Leader of the Melanoma/Renal Cancer Translational Research Team at Yale Cancer Center. Formerly with the National Cancer Institute (NCI), Dr. Sznol has an international reputation in cancer drug development. His expertise and experience are in cancer immunotherapy, drug development for cancer and treatment of patients with melanoma and renal cell carcinoma. He has contributed to the development of cytokines, cell therapies, co-stimulatory antibodies and immune checkpoint inhibitors, through the design, execution and analyses of clinical trials and clinical development plans as well as through direct patient care.

After completing a fellowship in medical oncology at Mount Sinai College of Medicine in 1987, he joined the NCI as a Senior Investigator in the Investigational Drug Branch (IDB), Cancer Therapy Evaluation Program (CTEP). From 1994-1999, Dr. Sznol was head of the Biologics Evaluation Program, IDB, CTEP where he was responsible for clinical development of multiple biological and immune therapy agents. In 1999, he left NCI to become Vice President of Clinical Development for Vion Pharmaceuticals. He joined the Yale faculty in medical oncology in 2004.

Taha Meghoub, PhD
Memorial Sloan Kettering Cancer Center
Taha Meghoub, PhD
Memorial Sloan Kettering Cancer Center

Dr. Taha Merghoub is the deputy director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine. His research centers on discovering and improving immunotherapies that more effectively harness immune responses to improve outcomes in patients with cancer. He received his BA degree from University of Algiers, Algeria, and MS and PhD degrees with highest distinction from University of Paris, France. His thesis work focused on the study of genetic polymorphism in fetal hemoglobin genes in patients with sickle cell anemia and thalassemia. His findings provided insight to the correlation of genotypes and phenotypes in sickle cell anemia and thalassemia. After graduation, he pursued his postdoctoral research with Dr. Pier Paolo Pandolfi at Memorial Sloan Kettering Cancer Center. He characterized the transcriptional properties of the Pokemon gene and its role during development. He also played an active role in the generation of laboratory models for acute promyelocytic leukemia and furthered his knowledge and experience in genetics.

Back to Top